... of protein degraders: proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs). Almost 70 years have passed since thalidomide was initially developed as a sedative-hypnotic drug, which is currently recognized as one of the most well-known MGDs. During the last two decades, a myriad...

... J , Cortés F , Cucurull E , Mauri M , Buján S , Vilardell M . Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy . J Rheumatol . 2000 ; 27 ( 6 ): 1429 ‐ 1433 . 2 Ordi J , Cortes F , Martinez N , Mauri M , De...

... at thalidomide, y 5.5 (3.5 to 7.2) 14.4 (13.2 to 15.7) <.01 Duration of disease, y 2.2 (1.0 to 3.2) 2.1 (1.0 to 3.0) .47 Disease activity PCDAI 29.7 (20.0 to 35.0) 35.0 (22.5 to 44.4) .80 PUCAI 41.6 (30.0 to 50.0) 43.0 (32.5 to 57.5) .83 Weight z score -0.51 (-1.40 to 0.01...

...Xiang Peng; Zi-Wen Lin; Min Zhang; Jia-Yin Yao; Jun-Zhang Zhao; Pin-Jin Hu; Qian Cao; Min Zhi Crohn’s disease thalidomide refractory clinical remission Disease response was defined as a minimal decline in CDAI of 100 points or CDAI <150 points. SES-CD scores calculated by colonoscopy of 0–2...

... of thalidomide and NO donors as explained. After 24 h of drug treatment, fennel seeds were incubated over wet cotton and exposed to dark in 150 mm dishes. Germination rate was documented on alternate days and was calculated as follows: Germination rate = seeds germinated/total seeds × 100. Fennel seeds were...

... Journals Publication Model ( https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights ) Behçet’s disease right abdominal pain vasculitis thalidomide Shandong Provincial Key Research and Development Program 2019JZZY011007 To the Editors, Behçet’s disease (BD) is a multisystemic vasculitis...

... 13 02 2021 22 03 2021 © 2021 The Chemical Society of Japan 2021 This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights ) Abstract Thalidomide, a famous...

...Catherine H Schein At this point, the mechanistic basis for using the thalidomide drug family in cancer becomes confusing, as they have pleiomorphic effects. For example, their anti-inflammatory activity has been linked to their ability to inhibit secretion of tumor necrosis factor (TNF)-α...

... of more targeted immunomodulatory agents, including thalidomide. Methods We describe a retrospective cohort of 38 children consecutively treated with adjunctive thalidomide for CNS TB–related complications over a 10-year period. Results The most common presenting symptom was focal motor deficit (n...

... the protein complexes influenced by a drug. We applied this approach to the analysis of thalidomide action on HepG2 cells, assessed the identified proteins by clustering data analyses, and assigned 135 novel protein complexes affected by the drug. We propose that this approach is applicable to elucidating...

... to impaired lung functions. In the present study, we aimed to investigate the antifibrotic activity of three compounds: pentoxifylline (PTX), azithromycin (AZT), and thalidomide (Thal) in a murine model of pulmonary PCM treated with itraconazole (ITC) or cotrimoxazole (CMX). BALB/c mice were inoculated...

..., immunomodulatory drugs (IMiDs) and proteasome inhibitors. Thalidomide was first developed as a sedative in 1950s, but it was withdrawn from the market because of teratogenicity. In 1990s, however, thalidomide received attention due to the discovery of its anticancer potential derived from antiangiogenic...

...Julie Parle; Ludger Wimmelbücker The early commercial successes and failures of the two companies played an important part in influencing sale routes for thalidomide. This is well-documented in the case of Grünenthal, which actively looked for foreign markets for its products, especially...

..., during maintenance therapy with oral thalidomide ( figures 1 and 2 ). Thyroid function was found normal. Thalidomide was suspended and therapy with acitrein 0.3 mg/kg body weight was started. After 1 month, the patient significantly improved his Psoriasis Area Severity Index (3 vs 18 before therapy...

... ^{, 19} Radiotherapy was rejected because of multiple bone lesions, and autologous stem-cell transplantation was rejected due to severe PAH. ⁷ More recently, thalidomide treatment has been shown to have decreased serum VEGF levels and improved clinical symptoms from randomized placebo...

... & Colitis Foundation 2017 Background Thalidomide is an effective therapy in children with inflammatory bowel disease refractory to standard treatments, but thalidomide-induced peripheral neuropathy (TiPN) limits its long-term use. We aimed to investigate the risk factors and the outcome of TiPN...

.../funder_policies/chorus/standard_publication_model ) Thalidomide mediates suppression of type-I interferons independently of cereblon Abstract Thalidomide and its derivatives, collectively referred to as immunomodulatory drugs (IMiDs), are effective inhibitors of inflammation and are known to inhibit TLR-induced...

... complicate cancer treatment and occur in patients receiving thalidomide. Increased awareness regarding this condition is needed among hemato-oncologists. Alanine aminotransferase and HCV RNA levels of HCV-infected patients receiving thalidomide should be monitored, and thalidomide may need to be dose-reduced...

... Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Abstract Background. The immunomodulatory drugs (IMiDs) thalidomide and lenalidomide have both been tested for treatment of mucosa-associated lymphoid tissue (MALT) lymphoma...

... ^{, 20} During the long-term follow-up, thalidomide could be tapered 6 months after the achievement of remission with a suggested reduction scheme of about 25% less every 6 months. This scheme could be adjusted in case of signs of clinical relapse (by increasing the daily dose of thalidomide) or in case...